Clinical trial
Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and…
NCT00191698 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191698 |
|---|---|
| Title | Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD |
| Official title | A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride and Placebo in Child and Adolescent Outpatients With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder |
| Intervention type | Drug |
| Interventions | atomoxetine hydrochloride, placebo |
| Enrollment | 226 |
| Start date | Dec 1, 2003 |
| Primary completion | Jun 1, 2005 |
| Completion | Nov 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Oct 31, 2008 |
| Countries | Australia, Belgium, Denmark, Finland, Germany, Netherlands, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: